Multianalyte markers of schizophrenia and bipolar disorder: A preliminary study

Schizophrenia Research

Volumn 168, Issue 1-2, 2015, Pages 450-455

  Dickerson, Faith ^a   Schroeder, Jennifer ^b   Stallings, Cassie ^a   Origoni, Andrea ^a   Bahn, Sabine ^c   Yolken, Robert ^d  

^a SHEPPARD PRATT HEALTH SYSTEM   (United States)

^b Schroeder Statistical Consulting   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Analytes; Bipolar disorder; Blood markers; Immune; Schizophrenia

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGE DISTRIBUTION; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EDUCATIONAL STATUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE ASSESSMENT; MOLECULAR DIAGNOSIS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RACE DIFFERENCE; RECEIVER OPERATING CHARACTERISTIC; REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; SCHIZOPHRENIA; SEX DIFFERENCE; SMOKING; YOUNG ADULT; BLOOD; CLASSIFICATION; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; PRINCIPAL COMPONENT ANALYSIS;

ADULT; BIOMARKERS; BIPOLAR DISORDER; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; PRINCIPAL COMPONENT ANALYSIS; ROC CURVE; SCHIZOPHRENIA;

EID: 84942365866     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.08.003     Document Type: Article

References (26)

1. Alsaif M., Guest P.C., Schwarz E., Reif A., Kittel-Schneider S., Spain M., Bahn S. Analysis of serum and plasma identifies differences in molecular coverage, measurement variability, and candidate biomarker selection. Proteomics Clin. Appl. 2012, 6(5-6):297-303.
2. Altamura A.C., Bertoldo A., Marotta G., Paoli R.A., Caletti E., Dragogna F., Brambilla P. White matter metabolism differentiates schizophrenia and bipolar disorder: a preliminary PET study. Psychiatry Res. 2013, 214(3):410-414.
3. Altamura A.C., Buoli M., Pozzoli S. Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: comparison with schizophrenia. Psychiatry Clin. Neurosci. 2014, 68(1):21-36.
4. APA Diagnostic and Statistical Manual of Mental Disorders 2013, Author, Washington, D.C. 5th ed.
5. Chan M.K., Gottschalk M.G., Haenisch F., Tomasik J., Ruland T., Rahmoune H., Bahn S. Applications of blood-based protein biomarker strategies in the study of psychiatric disorders. Prog. Neurobiol. 2014, 122:45-72.
6. Crisafulli C., Drago A., Calabro M., Spina E., Serretti A. A molecular pathway analysis informs the genetic background at risk for schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2015, 59:21-30.
7. Dacquino C., De Rossi P., Spalletta G. Schizophrenia and bipolar disorder: the road from similarities and clinical heterogeneity to neurobiological types. Clin. Chim. Acta 2015, pii: S0009-8981(15)00101-1.
8. Domenici E., Wille D.R., Tozzi F., Prokopenko I., Miller S., McKeown A., Muglia P. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 2010, 5(2):e9166.
9. Goodkind M., Eickhoff S.B., Oathes D.J., Jiang Y., Chang A., Jones-Hagata L.B., Etkin A. Identification of a common neurobiological substrate for mental illness. JAMA Psychiatry 2015, 72:305-315.
10. Guest P.C., Chan M.K., Gottschalk M.G., Bahn S. The use of proteomic biomarkers for improved diagnosis and stratification of schizophrenia patients. Biomark. Med 2014, 8(1):15-27.
11. Haenisch F., Alsaif M., Guest P.C., Rahmoune H., Dickerson F., Yolken R., Bahn S. Multiplex immunoassay analysis of plasma shows prominent upregulation of growth factor activity pathways linked to GSK3beta signaling in bipolar patients. J. Affect. Disord. 2014, 156:139-143.
12. Jobe T.H., Harrow M. Long-term outcome of patients with schizophrenia: a review. Can. J. Psychiatry 2005, 50(14):892-900.
13. Mamdani F., Martin M.V., Lencz T., Rollins B., Robinson D.G., Moon E.A., Vawter M.P. Coding and noncoding gene expression biomarkers in mood disorders and schizophrenia. Dis. Markers 2013, 35(1):11-21.
14. Muller N., Myint A.M., Krause D., Weidinger E., Schwarz M.J. Anti-inflammatory treatment in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 42:146-153.
15. Ortiz-Dominguez A., Hernandez M.E., Berlanga C., Gutierrez-Mora D., Moreno J., Heinze G., Pavon L. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 2007, 9(6):596-602.
16. Perkins D.O., Jeffries C.D., Addington J., Bearden C.E., Cadenhead K.S., Cannon T.D., Heinssen R. Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project. Schizophr. Bull. 2015, 41(2):419-428.
17. Ramsey J.M., Schwarz E., Guest P.C., van Beveren N.J., Leweke F.M., Rothermundt M., Bahn S. Distinct molecular phenotypes in male and female schizophrenia patients. PLoS One 2013, 8(11):e78729.
18. Schizophrenia Working Group of the Psychiatric Genetics Consortium Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014, 511(7510):421-427.
19. Schwarz E., Guest P.C., Rahmoune H., Harris L.W., Wang L., Leweke F.M., Bahn S. Identification of a biological signature for schizophrenia in serum. Mol. Psychiatry 2012, 17(5):494-502.
20. Schwarz E., Guest P.C., Rahmoune H., Martins-de-Souza D., Niebuhr D.W., Weber N.S., Bahn S. Identification of a blood-based biological signature in subjects with psychiatric disorders prior to clinical manifestation. World J. Biol. Psychiatry 2012, 13(8):627-632.
21. Schwarz E., van Beveren N.J., Ramsey J., Leweke F.M., Rothermundt M., Bogerts B., Bahn S. Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways. Schizophr. Bull. 2014, 40(4):787-795.
22. Sommer I.E., van Westrhenen R., Begemann M.J., de Witte L.D., Leucht S., Kahn R.S. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr. Bull. 2014, 40(1):181-191.
23. Thronson L.R., Pagalilauan G.L. Psychopharmacology. Med. Clin. North Am. 2014, 98(5):927-958.
24. Treuer T., Tohen M. Predicting the course and outcome of bipolar disorder: a review. Eur. Psychiatry 2010, 25(6):328-333.
25. van Beveren N.J., Schwarz E., Noll R., Guest P.C., Meijer C., de Haan L., Bahn S. Evidence for disturbed insulin and growth hormone signaling as potential risk factors in the development of schizophrenia. Transl. Psychiatry 2014, 4:e430.
26. Wadee A.A., Kuschke R.H., Wood L.A., Berk M., Ichim L., Maes M. Serological observations in patients suffering from acute manic episodes. Hum. Psychopharmacol. 2002, 17(4):175-179.